ORCHPHARMA2026-01-012026-03-31ORCHPHARMA2026-03-31ORCHPHARMA2025-03-31ORCHPHARMA2025-04-012026-03-31ORCHPHARMA2026-01-012026-03-31in-capmkt:OtherExpenses1MemberORCHPHARMA2025-04-012026-03-31in-capmkt:OtherExpenses1MemberORCHPHARMA2026-03-31OtherNoncurrentFinancialAssetsDomain1ORCHPHARMA2026-03-31OtherNoncurrentFinancialAssetsDomain2ORCHPHARMA2026-03-31OtherNoncurrentAssetsDomain1ORCHPHARMA2026-03-31OtherCurrentFinancialAssetsDomain1ORCHPHARMA2026-03-31OtherCurrentAssetsDomain1ORCHPHARMA2026-03-31OtherNoncurrentFinancialLiabilitiesDomain1ORCHPHARMA2026-03-31OtherCurrentFinancialLiabilitiesDomain1ORCHPHARMA2026-03-31OtherCurrentFinancialLiabilitiesDomain2ORCHPHARMA2026-03-31OtherCurrentLiabilitiesDomain1ORCHPHARMA2026-01-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss1ORCHPHARMA2025-04-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss1ORCHPHARMA2026-01-012026-03-31AuditorDomain1ORCHPHARMA2026-01-012026-03-31in-capmkt:AuditedMemberORCHPHARMA2026-03-31in-capmkt:AuditedMemberORCHPHARMA2026-01-012026-03-31in-capmkt:AdjustedMemberORCHPHARMA2026-03-31in-capmkt:AdjustedMemberORCHPHARMA2026-01-012026-03-31AuditQualification1iso4217:INRiso4217:INRxbrli:shares524372ORCHPHARMANOTLISTEDINE191A01027ORCHID PHARMA LIMITEDMain BoardEquity2025-04-012026-03-312026-08-142026-08-11INRLakhsQuarterlyFourth quarterSingle segmentPharmaceuticals2026-08-1414:00:002026-08-1418:15:00trueCash Flow IndirectStatement on impact of audit qualification2026-01-012026-03-31AuditedConsolidated368327100077737000376100800020983930004759000351234000276175000196390001090310006511150003510346000250662000-22020002484600000170001700002484430000009951000258394000130270002714210000000598852000104.314.31004.314.311. The above results for the quarter ended June 30 , 2026 as reviewed and recommended by the Audit committee of the Board, has been approved by the Board of Directors at its meeting held on Aaugust 14, 2026.The statutory auditors of the company have expressed an unmodified conclusion on the unaudited Standalone results and Consolidated results <br /> <br /> 2 The Statement has been prepared in accordance with the recognition and measurement principles of the Companies Indian Accounting Standards ("Ind AS") as prescribed under Section 133 of the Companies Act, 2013, read with the Companies (Indian Accounting Standards) Rules, 2015, as amended from time to time and other recognized accounting practices and policies generally accepted in India, to the extent applicable. <br /> <br /> 3 a) The Government of India had consolidated 29 existing labour legislations into a unified framework comprising four Labour Codes collectively referred to as the 'New Labour Codes', which became effective from 21st November 2025. However, the new Rules are yet be notified even as on date. <br /> During the quarter ended December 2025, based on its preliminary understanding of the new Labour Codes, the Company recognised a provision of Rs. 711 .27 lakhs towards incremental estimated liabilities for past service cost relating to gratuity and leave, which was disclosed under "Exceptional items". <br /> Thereafter, based on subsequent FAQ's and clarifications issued by the Ministry of Labour, deliberations at various forums and detailed examination of various provisions of the above new Labour Codes, the Company, based on Actuarial Valuation, has determined that the incremental estimated liabilities as on March 31, 2026 on account of past service cost in relation to Gratuity and Leave liability amounted to only Rs.733.29 Lakhs. Hence the differential provision of Rs.22.02 Lakhs has been made in the March 2026 quarter under "Exceptional items". <br /> The Company continues to monitor the finalisation of Central 1 State Rules and further clarifications from the Government on other aspects of the Labour Codes and will account for any additional impact, if required, based on such developments. <br /> <br /> 4. The entire net Proceeds of Rs.39180 Lakhs raised on 27th June 2023 by way of Qualified Institutional PLacement (QIP) was received by the Company and the Statement of Net funds raised and its utilisation as on June 30, 2026 furnished below : <br /> <br /> Statement of QIP Net Funds raised and utilisation <br /> Particulars Amount as stated in Total amount utilised * Balance amount as on Remarks <br /> the Offer Document upto June 30, 2026 on June 30, 2026 kept <br /> Rs. In Lakhs Rs. In Lakhs in Fixed Deposits in lakhs <br /> <br /> 1)Investment in OBPL, subsidiary, <br /> for setting up Jammu <br /> Manufacturing Facility 13500 9762 3738 <br /> 2)Repayment/prepayment, in <br /> full or in part, of certain <br /> outstanding borrowings <br /> availed by the company 19546 19546 - <br /> 3)Funding capital expenditure <br /> requirements for setting up a <br /> new block at the API facility <br /> of the Company in Alathur, <br /> Tamil Nadu 36 36 - <br /> 4)General corporate purposes 6372 6372 0 # <br /> Total 39454 35716 3738 <br /> # As per QIP Offer Document the amount allocated for General Corporate Purpose (GCP) was Rs. 6098 Lakhs which was based on the propsoed net proceeds after issue expenses being Rs.39180 Lakhs. However, net proceeds transferred to Monitoring Agency Account was Rs. 39454 Lakhs as against the proposed Net Proceeds of Rs. 39180 Lakhs, therefore surplus Amount of Rs. 274 Lakhs has been included in GCP Balance as on June 30, 2026. The allocation among the objects has been revised vide Shareholder's Resolution dated September 20, 2025. <br /> *Balamce amount excludes the interest earned on the Unutilized QIP funds kept in fixed deposits. <br /> <br /> 5. The operations of the Company falls under a single operating segment i.e., "Pharmaceuticals" in accordance with Ind AS 108 "Operating Segments" and hence no reporting as per Ind AS 108 is applicable. <br /> <br /> 6. The figures for the quarters ended 31st March, 2026 are the balancing figures between audited figures in respect of the full financial year and year to date figures up to the third quarter of the relevant financial years which were subjected to limited review. <br /> <br /> 7. In accordance to the provisions of Section 230-232 of the Companies Act, 2013 read with the applicable Rules made thereunder, the Board of Directors of Orchid Pharma Limited (“the Company” or “Transferee Company”) had approved the Scheme of Amalgamation and Arrangement between Dhanuka Laboratories Limited (“Dhanuka” or “Transferor Company”) and Orchid Pharma Limited and their respective shareholders and creditors (“the Scheme”), pursuant to which Dhanuka was proposed to be amalgamated with and into the Company, with April 01, 2024 as the Appointed Date. <br /> The Scheme was subsequently considered and sanctioned by the Hon’ble National Company Law Tribunal, Chennai Bench (“NCLT”) vide its order dated June 05, 2026. The Company obtained the certified copy of the said order and, upon filing of the same with the Registrar of Companies, Chennai, on July 10, 2026, the Scheme became effective (“Effective Date”). <br /> Pending receipt of the order of the Hon’ble NCLT and effectiveness of the Scheme, the financial results of the Company for the quarter and year ended March 31, 2026 were approved by the Board of Directors at its meeting held on May 25,2026, without giving effect to the Scheme. <br /> Subsequent to the approval of the financial results by the Board, the Scheme was sanctioned by the Hon’ble NCLT vide Order dated June 05, 2026 and which became effective on July 10, 2026. Accordingly, in accordance with the requirements of Appendix C to Ind AS 103 – Business Combinations, read with the applicable provisions of the Scheme, the amalgamation has been given effect to from the Appointed Date and the standalone and consolidated financial results for the quarter and year ended March 31, 2026 have been revised/restated solely to give effect to the amalgamation. The corresponding comparative information has also been revised, wherever applicable, to give effect to the amalgamation from the Appointed Date. The revision includes the consequential impact of the amalgamation on the assets, liabilities, equity, reserves and other relevant financial statement items of the Company. <br /> The revision of the standalone and consolidated financial results has been carried out solely for giving effect to the aforesaid amalgamation pursuant to the Scheme, and no other adjustments have been made to the financial results originally approved by the Board of Directors on May 25, 2026, except for those consequentially arising from the accounting of the amalgamation. <br /> <br /> 8 The Company has successfully completed the acquisition of 100% assets of Allecra Therapeutics GmbH, Germany and Allecra Therapeutics SAS, France on October 29,2025 and August 01,2025 respectively. After the successful completion of above transactions, Orchid Pharma Limited now possesses 100% global ownership of Enmetazobactam (International Brand Name known as EXBLIFEP) (known as Orblicef in India), consolidating rights and control previously split across entities. This will mark the full repatriation of the first novel antibiotic molecule discovered in India, back to India. <br /> <br /> 9 The Company have acquired 100% Share Capital of Weilchensee 1272. V V GmbH, a Company incorporated under laws of Germany, now a Wholly owned subsidiary renamed as Orchid Pharma Europe GmbH w.e.f. July 30, 2025. <br /> <br /> 10 Figures of the previous period have been regrouped/reclassified/restated wherever considered necessary.2025-04-012026-03-31AuditedConsolidated1232778400036418300012691967000771391600016872000713839000117654600089843000432463000237087100012514350000177617000-733290001042880000-1916000-19160000106204000000-66130009959100013176000112767000000059885200010150442180001.661.66001.661.66Other Expenses651115000Other Expenses23708710006866078000340521100000595900073079800000669659000001154010007850600005990610008994650001329163200037231100000381350100070730000764460000012946000466163700029280009049700009292645000002258427700059885200015044218000156430700000156430700001847370000000472480001894618000134493000020291110001167017000102975000336411300034670880001728700046513920002526600008044000491209600000694120700022584277000Right to use Assets49289000Other financials assets66112000Other non-current assets899465000Other current financial assets12946000Other current assets904970000lease liabilities47248000lease liabilities3854000Other current financial liabilities13433000Other current liabilities25266000089843000850543000-3960520000-18579100004536000002924030000004324630000014315600000-81876000-8000-894150000066130000-324184000922200013220200010492750001153563000000-235280007928200012563730000010761000000022617700090923000389620600000000000000000000800012182600001130070000-276879500000000000170084800022852300000100950000001371375000-1410470000-14104700021177700070730000Items that will not be reclassified to profit or loss1302700013027000Items that will not be reclassified to profit or loss131760001317600000001302700013176000AuditedQualified opinionSinghi & Co.true2028-08-311232778400012327784000122281930001222819300099591000995910001.661.662258427700022584277000694120700069412070001564307000015643070000The Consolidated Financial Statements for the year ended March 31, 2026 include the financial statements for the year ended March 31, 2026, of the following subsidiary companies: <br /> (i) Orchid Pharmaceuticals Inc., USA <br /> (ii) Bexel Pharmaceuticals Inc., USA <br /> (iii) Diakron Pharmaceuticals, Inc. USA <br /> <br /> We did not audit the financial statements of the above subsidiaries whose financial statements reflect total Assets of Rs.385.59 Lakhs as at March 31, 2026, total revenue from operations of Rs. Nil, total comprehensive income after tax of Rs.Nil for the quarter and year ended March 31, 2026 and net cash flows amounting to Rs. Nil for the year ended on that date as considered in the consolidated financial statements. <br /> <br /> The financial statements of the above subsidiaries are unaudited and have been furnished to us by the management and our opinion on the Consolidated financial statements, in so far as it relates to the amounts and disclosures included in respect of the subsidiaries, is based solely on such unaudited financial statements. Accordingly, we do not express any opinion on the completeness and true and fair view of the financial statements, including adjustments, if any, required on the carrying amount of assets and liabilities of the above subsidiaries and foreign currency translation reserve as at March 31, 2026 included in the consolidated financial statements. This has also been qualified in the Limited Review reports of the earlier quarters and audit reports of the earlier years. <br /> Qualified opinionRepetitiveNot ApplicableNot Applicable <br /> The subsidiaries of the Company are located in USA. Audit is not compulsory for companies in USA, if they are not publicly traded. Further transactions in majority of the above subsidiaries are either Nil or insignificant. Hence the management has used unaudited financials for the purpose of consolidationRefer, Basis for Qualified Opinion, in our audit reportManish DhanukaSunil Kumar GuptaManoj GoyalSinghi & Co.Gurugram2026-08-14